Demetrios Braddock was born in Tennessee, educated at the University of Chicago, trained at the NIH in Anatomic Pathology and Biophysical Chemistry, and came to Yale in 2004. He practices Hematopathology and leads a laboratory that studies the ENPP enzymes – a family of extracellular enzymes that create small molecules in the extracellular environment that regulate organismal homeostasis in processes such as hemostasis, bone mineralization, and vascular development. We are especially interested in a rare disease of lethal vascular calcifications called 'Generalized Arterial Calcification of Infancy' (GACI) associated with ENPP1 deficiency, and designed and validated an enzyme therapy that was curative in a mouse model of GACI. We are now moving this therapy into patients in collaboration with a company we founded (Inozyme Pharma). We have also identified a form of early onset osteoporosis associated with ENPP1 deficiency, and are investigating the role of ENPP1 in low bone mass and increased tissue calcification, a medical condition called 'Paradoxical Mineralization' which occurs in the general medical population in conditions such as aging and chronic kidney disease.
Pathology Research Faculty
- Primary & Secondary
- By Research Area
Pathology Research Faculty - Primary
José Costa, MD, FACP, is Professor Emeritus of Pathology at Yale University School of Medicine and Professeur Honoraire at the University of Lausanne Switzerland. Dr. Costa is an internationally renowned leader in the field of diagnostics of cancer and pathogenesis of tumor formation. Having contributed to the transition from opinion-based medicine to evidence-based diagnosis, he is now making use of novel tools to practice integrative systems pathology, an approach that strives to enable a personalized, predictive and precise diagnosis.
Prior his transition to Emeritus status April 1, 2018, at the Yale School of Medicine, Dr Costa served in several positions of leadership that include: Chief of the Anatomical Pathology Branch at the Clinical Center, NIH Bethesda Md (1980-83); Director of the Institute of Pathology, University of Lausanne, Lausanne, Switzerland (1983-1993); President of the Board of Directors of the Centre Pluridisciplinaire d’Oncologie, Lausanne Switzerland (1985-1992); Director of Anatomical Pathology Yale New Haven Hospital (1993-2007); and Deputy Director of the Yale Comprehensive Cancer Center (1995-2007). He is a sought-after advisor to several academic, research, and health organizations, and has served or currently serves as board member or advisor to several institutions including the ISREC (Swiss Cancer Research Institut); the Ludwig Institut Branch in Lausanne; the Deutsche Krebs Forschung Zenter (Heidelberg); the Institut of Molecular Pathology at Porto (Portugal); The Catalan Institut of Oncology [ICO] Barcelona, Spain; the Centro Nacional de Investigacion en Oncologia [CNIO] Madrid,Spain, the Instituto Carlos III, Madrid, Spain, the Center for Virtual Tumor Modeling (Harvard); the NIH Consensus Panels and the NCI’s EDRN in Bethesda, MD, USA.
Throughout his career, Dr. Costa has integrated advances in basic understanding of cancer to the clinical area of diagnosis, prognosis, and early detection. He has contributed over 170 original publications to the technical literature, and is among a small group of investigators using evolutionary and ecological theory to predict tumor behavior. His laboratory investigates the micro-evolutionary dynamics involved in tumor formation and tumor progression using both experimental and theoretical modeling at the systems level. This work has identified novel and promising ways to detect early cancer and ways to follow the changes in tumors under therapy. Dr. Costa is co-inventor of two novel diagnostic technologies and has served in the oversight board of Yale’s Office of Cooperative Research. He has also been involved in the crafting of public-private joint ventures in Switzerland (IP-AMS Labs ), the early launching of Curagen Corporation (New Haven, CT ), the founding of Aureon Biosciences (Yonkers, NY ), VCN (Barcelona, Spain ), and PetaOmics (San Marcos, TX ).
The contributions of Dr. Costa have been recognized by several awards, including a Special Achievement Award from NIH, election as a Fellow to the American Association for the Advancement of Science (2003), the Gold Medal of the International Academy of Pathology. and the Trueta Medal from the Catalan government for contributions to public health.
A firm believer in the dynamics coming from multi-disciplinarity and cooperation, Dr. Costa continues to create an environment that will transform health care and set the standards for the 21st century. He is particularly interested in exploring synergies between academia, private industry, and governmental programs.
Karin Finberg received her B.S., M.D., and Ph.D. degrees from Yale. Her Ph.D. dissertation with Dr. Richard Lifton in the Department of Genetics focused on the genetic basis of an autosomal recessive disorder of systemic pH homeostasis, distal renal tubular acidosis with sensorineural deafness. After graduating from Yale, Karin completed residency training in Clinical Pathology at Massachusetts General Hospital and clinical fellowship training in the Harvard Medical School Molecular Genetic Pathology Training Program based at Brigham and Women’s Hospital. She then completed postdoctoral research training in the laboratory of Dr. Nancy Andrews, first at Children’s Hospital Boston and later at Duke University Medical Center, where she employed genetic study of patients with an inherited form of iron deficiency anemia to shed insight into mechanisms of systemic iron regulation. In her research laboratory at Yale, Karin continues to investigate mechanisms of iron balance through genetic study of patients with iron-related phenotypes and through characterization of genetically targeted mouse models. She also contributes to patient care as a molecular genetic pathologist in the Molecular Diagnostics Unit of the Department of Pathology.
Pallavi Gopal is a graduate of the Medical Scientist Training Program at the University of Pennsylvania, Perelman School of Medicine in Philadelphia. Her Ph.D. thesis work in Neuroscience with Dr. Jeffrey Golden focused on understanding the cellular and molecular mechanisms that guide neuronal migration during forebrain development. After earning her M.D., Pallavi completed postgraduate clinical training in Anatomic Pathology and Neuropathology at the Hospital of the University of Pennsylvania. She did her postdoctoral research training with Dr. Erika Holzbaur at the University of Pennsylvania. Dr. Gopal is a recipient of the NINDS Clinical Scientist Research Career Development Award. She joined the Pathology Department at Yale School of Medicine in January 2018.
My major interests are in diagnostic and experimental lung pathology.
I entered the MD-PhD program at Yale School of Medicine in 1979. My PhD with Donal Murphy described a novel antigenic structure within the murine MHC. Upon graduation I trained in Anatomic Pathology under the supervision of Dr. Juan Rosai and simultaneously completed a post-doctoral fellowship with Richard Flavell, chair of the section of immunobiology, with a focus on T cell tolerance.
For many years, I worked on various murine models of inflammatory lung disease, ran an NIH funded morphology core for the Yale pulmonary section and ran a laboratory at West Haven VA looking at murine models of pulmonary fibrosis. I now still consult on various experimental models of lung disease and work with collaborators analyzing human fibrotic and neoplastic disease.
I am heavily involved in medical school curriculum development as Director of Medical Studies for Pathology, am on the curriculum committee and am Co-Director of one of the new master courses for the new (starting 2015) pre-clinical curriculum for YSM.
I have been Director of Anatomic Pathology at West Haven VA since 1994. I have been lead thoracic pathologist at Yale since 2004.
Dr. Hudnall is an AP/CP board certified hematopathologist with a special interest in lymphoproliferative disorders and the role of chronic inflammation and tumor-infiltrating lymphocytes and monocytes in tumor progression. Dr. Hudnall is also interested in the role of infectious agents in lymphoproliferative disorders, with a special interest in herpes viruses.
Dr. Hui is Professor in the Department of Pathology and Department of Obstetrics, Gynecology and Reproductive Sciences at Yale School of Medicine. He received combined anatomic and clinical pathology residency training at Yale-New Haven Hospital in 2000, followed by Oncological Pathology Fellowship training at MSKCC. He joined the pathology faculty at Yale in 2001 and became full professor in 2013. Dr. Hui is a board certified surgical pathologist with clinical specialty areas including gynecologic pathology and molecular diagnostics. Currently, he is Director of Gynecologic Pathology Service, Clinical director of the Molecular Diagnostics Laboratory and Director of Gynecologic Pathology Fellowship Program.
Dr. Hui oversees a dynamic, high volume gynecologic pathology service at Yale. One of his long-term academic goals is to build an outstanding gynecological pathology program with emphasis on diagnostic tissue evaluation, oncological biomarker identification and clinical applications, and understanding the pathogenesis of various gynecological cancers. Dr. Hui has particular clinical expertise in the diagnostic workup of gestational trophoblastic disease. He serves on the editorial boards of International Journal of Gynecological Pathology, Modern Pathology, Human Pathology and Journal of Clinical Pathology. He has authored over 200 publications and written three pathology textbooks including Cytology and Surgical Pathology of Gynecologic Neoplasms, Gestational Trophoblastic Disease: Diagnostic and Molecular Genetic Pathology, and Atlas of Intraoperative Frozen Section Diagnosis in Gynecologic Pathology. Dr. Hui was a member of the consensus and editorial working group for the 4th edition of WHO Blue Book of tumor classifications of female reproductive organs. Currently he is an expert member of the editorial board for the 5th edition of WHO Blue Book of GYN tumor classifications. In both editions of the WHO blue book, Dr. Hui is the responsible editor/author for the WHO classification of gestational trophoblastic disease. Dr. Hui serves on the Board of Directors of the International Society of Gynecological Pathologists (ISGyP) and is the treasurer of the society.
Michael Kashgarian is professor emeritus of and senior research scientist in pathology. He received his medical degree from Yale School of Medicine in 1958, completed his residency in pathology at the Yale-New Haven Medical Center in 1963, and completed a fellowship in laboratory medicine at Yale-New Haven Hospital in 1964. While on the Yale faculty he established a diagnostic renal pathology and electron microscopy laboratory that bears his name. He was also a pioneer in understanding the process of organ rejection. Although Kashgarian has retired, he continues to be active in the diagnosis of renal and cardiac biopsies.
Samuel G. Katz graduated with a combined B.S./M.S. from Yale University in 1995. He then pursued dual M.D., Ph.D. training in the Health Sciences & Technology (HST) program jointly administered by MIT and Harvard. His Ph.D. thesis with Stuart H. Orkin focused on the transcriptional regulation of hematopoiesis. Sam then completed a residency in pathology and fellowship in hematopathology at Brigham and Women’s Hospital. He performed his post-doctoral studies on apoptosis with Loren D. Walensky at the Dana Farber Cancer Institute. As an Associate Professor of Pathology at Yale University, Dr. Katz manages a laboratory concentrating on both intrinsic mechanisms of cell death and ways to reprogram immunocytes to mediate the extrinsic program of cell death, as well as contributes to patient care as an active hematopathologist.
Dr. Steven Kleinstein is a computational immunologist with a combination of "big data" analysis and immunology domain expertise. His research interests include both developing new computational methods and applying these methods to study human immune responses. Dr. Kleinstein received a B.A.S. in Computer Science from the University of Pennsylvania and a Ph.D. in Computer Science from Princeton University. He is currently Professor of Pathology (with a secondary appointment in Immunobiology) at the Yale School of Medicine, and a member of the Interdepartmental Program in Computational Biology and Bioinformatics (CBB), and the Human and Translational Immunology Program.
Specific areas of research focus include:
- High-throughput B cell receptor (BCR) repertoire profiling (AIRR-seq or Rep-seq)
- Immune signatures of human infection and vaccination responses
Dr. Kyriakides completed a PhD at Washington State University in 1993. He did a postdoctoral fellowship at the University of Washington. His lab at Yale studies the the foreign body response to biomaterials and nanomaterials. In addition, Dr. Kyriakides studies nanomaterials and cell interactions with a focus on biosensing. Finally, ongoing efforts in the lab include engineering of tissue constructs to stimulate healing in mouse models of diabetes. He is Director of Graduate Studies for the Experimental Pathology PhD program. He also serves as a mentor for students from the School of Engineering and Applied Science.
Morgan Levine is a ladder-rank Assistant Professor in the Department of Pathology at the Yale School of Medicine and a member of both the Yale Combined Program in Computational Biology and Bioinformatics, and the Yale Center for Research on Aging. Her work relies on an interdisciplinary approach, integrating theories and methods from statistical genetics, computational biology, and mathematical demography to develop biomarkers of aging for humans and animal models using high-dimensional omics data. As PI or co-Investigator on multiple NIH-, Foundation-, and University-funded projects, she has extensive experience using systems-level and machine learning approaches to track epigenetic, transcriptomic, and proteomic changes with aging and incorporate this information to develop measures of risk stratification for major chronic diseases, such as cancer and Alzheimer’s disease. Her work also involves development of systems-level outcome measures of aging, aimed at facilitating evaluation for geroprotective interventions. A number of the existing biological aging measures she has developed are being applied in both basic and observational research.
Zachary Levine is currently an Assistant Professor of Pathology at the Yale School of Medicine and the Graduate School at Yale University. His training is in computational biophysics and his interests have recently expanded into solution biophysics techniques in amyloid protein systems. Many of his projects combine atomistic models with solution NMR spectroscopy in order to better understand the physical and thermodynamic determinants of age-related diseases.
In particular, we work to understand protein aggregation diseases from a biophysical perspective. Many of these conditions involve a toxic accumulation of amyloid proteins and plaques over the lifecourse, leading to degenerative dysfunction and death. By combining molecular models of protein folding and aggregation with solution biophysics techniques, we can deduce and modify thermodynamic landscapes that are distinctly pathological in order to mitigate human diseases.
- I am a graduate of Yale College (BA 1957), Oxford University (D.Phil.1961) and the Yale School of Medicine (MD, 1963). I trained in anatomical pathology at Washington University (1963-65), spent a post-doctoral year at Rockefeller University with George Palade, and served in the USPHS at the NIH from1966 to 1972.
I was recruited to Yale by Lewis Thomas in 1972, and a year later was named the Anthony N. Brady Professor of pathology and chair of the department and Pathologist-in-Chief of the Yale New Haven Hospital. In 1991 I became the Director of the Boyer Center for Molecular Medicine. I am a member of the National Academy of Sciences and the Institute of Medicine.
Wang Min, Ph.D., received his B.S. degree in Microbiology from Wuhan University in 1984, his M.S degree in Cell Biology at Shanghai Institute of Cell Biology, Chinese Academy of Sciences, in 1989, and his Ph.D degree in Genetics at University of Wales, Swansea, U.K., in 1993. He then performed 4-year post-doctoral training in vascular biology and immunology at the Department of Pathology, Yale School of Medicine. He became a Senior Scientist and Project Leader at GeneMedicine, Inc., in 1997 and then an Assistant Professor at University of Rochester, NY, in 1999. In 2003, he was recruited back to Department of Pathology and Vascular Biology Program at Yale School of Medicine, where he was promoted to Professor with Tenure in 2013. Dr. Min is a member of NAVBO, AHA, Yale Stem Cell Center and Yale Cancer Center. The goal in Dr. Min's lab is to dissect the signaling pathways, establish mouse models, and define the fundamental mechanisms involved in vascular development, remodeling, and repair related to human diseases such as vascular malformation, ischemia, and stroke. Dr. Min's lab has extensively employed biochemical, cell biological, and mouse genetic approaches to define the critical molecules mediating vascular development, remodeling, and repair. Dr. Min serves on the editorial board of Arteriosclerosis, Thrombosis, and Vascular Biology and Frontiers in Physiology. Dr. Min has been the recipient of many awards, including the Irvine H. Page Young Investigator Research Award, the AHA Established Investigator Award, the JACC Parmley Award, and CT Stem Cell EIA Award.
Dr. Moeckel graduated magna cum laude from Ludwig Maximillians University in Munich, Germany. He trained in anatomic and clinical pathology at the University of Arizona, Tucson, AZ and was on faculty in the Department of Pathology at Vanderbilt University, Nashville, TN prior to his recruitment as Director of the Renal Pathology and Electron Microscopy Laboratory at Yale University. His academic interests are in clinical renal pathology and research of mechanisms of kidney injury repair and progression of chronic kidney disease. Dr Moeckel is a fellow of the American Society of Nephrology and a Diplomat of the American Board of Pathology. He has published numerous papers in peer reviewed journals and has received private industry and federal grants to support his research.